OpinionPublished 9 October 2026The N2 dilemma in stage III NSCLC: toward a quantitative framework for trial designLuca Bertolaccini · Monica Casiraghi · Antonio Mazzella · Giorgio Lo Iacono · Lorenzo SpaggiariFrontiers in Oncologydoi 10.3389/fonc.2026.1866606
ReviewPublished 23 September 2026Therapeutic reprogramming of natural killer cells for solid tumors: expanding frontiers into rare and ultra-rare malignanciesFrancesca Rosato · James W. HodgeFrontiers in Molecular Biosciencesdoi 10.3389/fmolb.2026.1955532
ReviewPublished 9 July 2026Targeting glucocorticoid receptor signaling in platinum-resistant ovarian cancer: translational rationale and clinical advances following the ROSELLA trialWenxiang Wang · Zhanghuan Li · Junjie Zhao · Mengyuan Chang · Yafang Zhang · Xiangyi Shen · Junming Yue · John Schorge · Wenjing ZhangOncology Reviewsdoi 10.3389/or.2026.1861081
